Ye Jingjing, Jia Jue, Dong Sijing, Zhang Caili, Yu Shuqin, Li Lianxi, Mao Chaoming, Wang Dong, Chen Junjian, Yuan Guoyue
aDepartment of Endocrinology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu bDepartment of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Eur J Cancer Prev. 2014 May;23(3):158-65. doi: 10.1097/CEJ.0b013e328364f293.
Adiponectin is an important adipokine exclusively secreted from adipose tissue. Growing evidence suggests that adiponectin inhibits the growth of cancer cells and reduces cancer risk. Many studies have examined the association between circulating adiponectin levels and the risk of breast cancer. However, the results of numerous epidemiological studies have been inconsistent. The aim of the present study was to conduct a systematic review and a meta-analysis on the association between circulating adiponectin levels and the risk of breast cancer. PubMed, MEDLINE, EMBASE, and ISI Web of Science were searched to identify all observational studies that examined the relationship between circulating adiponectin and breast cancer. Standard mean difference (SMD) values and 95% confidence intervals (CIs) were estimated and pooled using the meta-analysis methodology. Summary effect estimates were derived using a random effects meta-analysis model. The analysis included eight studies that met the study criteria and described the relationship between circulating adiponectin levels and breast cancer. A total of 1803 participants and 885 cases of breast cancer were included in this meta-analysis. Serum total adiponectin concentrations were lower in patients with breast cancer, with a pooled SMD of -0.39 μg/ml (95% CI -0.618 to -0.161, P=0.001). However, adiponectin levels were not associated with the risk of breast cancer in premenopausal women [four studies, random effects SMD=0.02 μg/ml (95% CI -0.164 to 0.204, P=0.829)]. These results collectively suggest that lower adiponectin levels are associated with a higher risk of breast cancer in postmenopausal women.
脂联素是一种仅由脂肪组织分泌的重要脂肪因子。越来越多的证据表明，脂联素可抑制癌细胞生长并降低癌症风险。许多研究已探讨循环脂联素水平与乳腺癌风险之间的关联。然而，众多流行病学研究的结果并不一致。本研究的目的是对循环脂联素水平与乳腺癌风险之间的关联进行系统评价和荟萃分析。检索了PubMed、MEDLINE、EMBASE和ISI Web of Science，以识别所有检验循环脂联素与乳腺癌之间关系的观察性研究。使用荟萃分析方法估计并汇总标准平均差（SMD）值和95%置信区间（CI）。采用随机效应荟萃分析模型得出汇总效应估计值。该分析纳入了八项符合研究标准并描述循环脂联素水平与乳腺癌之间关系的研究。本荟萃分析共纳入1803名参与者和885例乳腺癌病例。乳腺癌患者的血清总脂联素浓度较低，汇总SMD为-0.39μg/ml（95%CI-0.618至-0.161，P=0.001）。然而，绝经前女性的脂联素水平与乳腺癌风险无关[四项研究，随机效应SMD=0.02μg/ml（95%CI-0.164至0.204，P=0.829）]。这些结果共同表明，绝经后女性脂联素水平较低与乳腺癌风险较高相关。
